Want to see TSE:OTC full AI Analyst Report?
OTC Stock Chart & Stats
C$0.55
C$0.02(6.45%)
At close: 4:00 PM EST
C$0.55
C$0.02(6.45%)
Day’s Range― - ―
52-Week RangeC$0.35 - C$1.99
Previous CloseN/A
Volume36.17K
Average Volume (3M)77.99K
Market Cap
C$26.01M
Enterprise ValueC$37.05M
Total Cash (Recent Filing)C$436.82K
Total Debt (Recent Filing)C$5.70M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding57,789,104
10 Day Avg. Volume70,232
30 Day Avg. Volume77,988
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized IOL TechnologyThe company’s focus on an accommodating intraocular lens is a durable strategic asset: a proprietary ophthalmic device that, if clinically validated and approved, can create differentiated clinical value and recurring adoption in cataract procedures, supporting long-term product revenue and service opportunities.
Focused R&D To Commercialization PathA clear corporate emphasis on R&D and an explicit regulatory/commercialization pathway increases the structural likelihood of eventual market entry. Sustained focus on approvals aligns resources, partnerships and clinical work toward scalable device commercialization once milestones are met.
Lean Operating FootprintA very small employee base implies a lean cost structure and operational agility, which can extend runway and enable targeted use of capital for clinical and regulatory milestones. For an R&D-stage medtech company, low fixed overhead helps preserve funds between financing events.
Bears Say
No Revenue; Growing Net LossesThe absence of revenue combined with materially widening net losses is a fundamental risk: without product sales, the company relies entirely on financing to fund operations. Continued escalating losses increase dilution risk and shorten the time horizon to achieve self-sustaining cash generation absent new commercial traction.
Persistent Negative Cash FlowConsistent operating and free cash flow deficits indicate structural cash burn that necessitates repeated external funding. This reduces strategic flexibility, constrains investment in commercialization or scale-up, and elevates execution risk if capital markets or financings become less accessible.
Deteriorated Balance Sheet & Rising DebtSharp debt growth and deeply negative equity materially weaken financial resilience. High leverage against a small asset base reduces borrowing capacity, raises refinancing risk, and likely forces dilutive equity raises or restructuring, limiting the company's ability to fund clinical/commercial milestones independently.
Ocumetics Technology Corp News
OTC FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
Ocumetics Technology Corp lowest stock price was C$0.35 and its highest was C$1.99 in the past 12 months.
What is Ocumetics Technology Corp’s market cap?
Ocumetics Technology Corp’s market cap is C$26.01M.
When is Ocumetics Technology Corp’s upcoming earnings report date?
Ocumetics Technology Corp’s upcoming earnings report date is Sep 01, 2026 which is in 61 days.
How were Ocumetics Technology Corp’s earnings last quarter?
Currently, no data Available
Is Ocumetics Technology Corp overvalued?
According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued.
Does Ocumetics Technology Corp pay dividends?
Ocumetics Technology Corp does not currently pay dividends.
What is Ocumetics Technology Corp’s EPS estimate?
Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocumetics Technology Corp have?
Ocumetics Technology Corp has 57,789,104 shares outstanding.
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
Currently, no hedge funds are holding shares in TSE:OTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the eye's natural lens compartment, offering a solution that eliminates the need for external vision correction. The company maintains its corporate headquarters in Calgary, Canada.
Technical Analysis
Aurora Spine
―
Covalon Technologies
―
Perimeter Medical Imaging AI
―
VentriPoint Diagnostics
―
Conavi Medical
―
Options Prices
Currently, No data available
---